ライフサイエンスコーパス: splenectomy

1 asive bacterial infection, notably following splenectomy.

2 onset, intravascular hemolysis, and previous splenectomy.

3 re reviewed, identifying those who underwent splenectomy.

4 plenectomy and depends on the indication for splenectomy.

5 ed with 1.7% in patients who did not undergo splenectomy.

6 ate (>/=90 days; HR 1.5 [CI, 0.9-2.6]) after splenectomy.

7 iesis-dependent iron consumption by means of splenectomy.

8 ents with refractory disease usually require splenectomy.

9 76 patients with ITP, 1762 of whom underwent splenectomy.

10 of response to rituximab and the response to splenectomy.

11 -8.5]) and late (HR 2.7 [CI, 1.9-3.8]) after splenectomy.

12 nosis of accessory spleens in patients after splenectomy.

13 cancers, granulomatous disease, or previous splenectomy.

14 , 1.39-2.01) among the 19 states in rates of splenectomy.

15 gths, and more commonly involved concomitant splenectomy.

16 nts were incidences of treatment failure and splenectomy.

17 ents develop massive splenomegaly or undergo splenectomy.

18 extramedullary hematopoiesis and preventing splenectomy.

19 of IgM(+) CD27(+) memory B cells found after splenectomy.

20 ell ablative therapies such as anti-CD20 and splenectomy.

21 , but fails to protect septic mice following splenectomy.

22 ear lower following rituximab than following splenectomy.

23 y is before splenectomy, or after failure of splenectomy.

24 ti-D, intravenous immunoglobulin (IVIG), and splenectomy.

25 patient), AMR was treated with laparoscopic splenectomy.

26 to standard therapy (ST) who resolved after splenectomy.

27 rocedural management, angioembolization, and splenectomy.

28 ease from bone marrow, a process enhanced by splenectomy.

29 ent urgent right hepatic artery ligation and splenectomy.

30 n the outcomes of ITP patients refractory to splenectomy.

31 9.6% (88 of 921 patients) with laparoscopic splenectomy.

32 ) had gastric variceal bleeding and required splenectomy.

33 reported consistently predicted response to splenectomy.

34 to undergo an MRI scan, or had a history of splenectomy.

35 of thrombotic events that is augmented after splenectomy.

36 sthesia, instrumentation for monitoring, and splenectomy.

37 cannot tolerate, or are unwilling to undergo splenectomy.

38 t an ITP second-line treatment: Rituximab or splenectomy.

39 Overall, 9 (20%) donors underwent splenectomy.

40 n causing severe infection in patients after splenectomy.

41 of severe sepsis and septic shock following splenectomy.

42 This defect resolved after splenectomy.

43 o patients who received observation required splenectomy.

44 patient underwent total pancreatectomy with splenectomy.

45 nd 1 patient had a distal pancreatectomy and splenectomy.

46 hospitalized during 2004-2013, 67 underwent splenectomy.

47 nd stress the relevance of vaccination after splenectomy.

48 mplications and mortality following elective splenectomy.

49 e common for all other procedures, including splenectomy (0.7% MIS), common bile duct exploration (24

50 twenty-three children underwent laparoscopic splenectomy (211 total; 12 partial) by the lateral appro

51 management strategy (195 patients undergoing splenectomy [23.6%], 70 undergoing angioembolism [23.9%]

52 index hospitalization, 825 (21.8%) underwent splenectomy, 293 (7.7%) underwent angioembolization, and

53 05) with a trend toward worsened response to splenectomy (3 of 18, 17%; vs 36 of 86, 42%; P = .06).

54 Of 33,131 patients, 26.2% underwent splenectomy, 6.1% died, and median hospital costs were $

55 leen in ischemic injury, we found that prior splenectomy (-7d) or chemical sympathectomy of the splee

56 Finally, splenectomy abrogated the enhancing effects of poly (I:C

57 led hypertension, previous aneurysm surgery, splenectomy, acute aortic dissection, aneurysm type, old

58 1), trocar site hernia (1), subsequent total splenectomy after an initial partial (1), and recurrent

59 However, the chance of readmission for splenectomy after initial nonoperative management was 1.

60 predicted sustained responses whereas prior splenectomy, age, sex, and duration of ITP did not.

61 the frequency of surgical complications with splenectomy all remain uncertain.

62 hest tube malfunction and conversion to open splenectomy); all were related to complications of surge

63 afts with this severe AMR phenotype by using splenectomy alone (n=14), eculizumab alone (n=5), or spl

64 very high load of PCs may not be rescued by splenectomy alone and may need additional treatments.

65 These data suggest that splenectomy alone may not be the sole reason for loss of

66 udies show that corticosteroid treatment and splenectomy, alone or together, increase platelet counts

67 There was more chronic glomerulopathy in the splenectomy-alone and eculizumab-alone groups at 1 year,

68 At a median follow-up of 533 days, 4 of 14 splenectomy-alone patients experienced graft loss (media

69 Splenectomy also was performed less frequently in patien

70 s 11.1% among the ITP patients who underwent splenectomy and 10.1% among the patients who did not.

71 Gender, age, ABO blood-type, cold ischemia, splenectomy and allograft type were significant DSA pred

72 However, splenectomy and anti-CD20 is associated with an increase

73 is high in patients who previously underwent splenectomy and depends on the indication for splenectom

74 defined as a normal platelet count following splenectomy and for the duration of follow-up with no ad

75 ecommended only in patients at high risk for splenectomy and in those not willing to undergo surgery.

76 actors that improved platelet responses were splenectomy and increasing patient age.

77 ), and 4 months after transplantation (after splenectomy and on maintenance immunosuppression).

78 The interval between splenectomy and OPSI was 6 years (range, 1 month-50 year

79 discuss criteria for treatment, the roles of splenectomy and other treatment options along with their

80 Associations between incidental splenectomy and risk of mortality and severe infections

81 As second-line therapy, splenectomy and Rituximab are both recommended.

82 the treatment of the disease has changed as splenectomy and rituximab have been shown to have unexpe

83 est triage model for decision making between splenectomy and SAE (AUC, 0.84).

84 Unlike adrenalectomy, splenectomy and splenic neurectomy prevent the anti-infl

85 cells promote MPE formation, as indicated by splenectomy and splenocyte restoration experiments.

86 und in patients (n=3) who did not respond to splenectomy and subsequently underwent bortezomib treatm

87 sly defined as lack of a minimum response to splenectomy and the requirement for long-term treatment

88 of studies comparing second-line options to splenectomy and to each other.

89 All patients in group 1 underwent emergent splenectomy, and all patients in group 2 were initially

90 hes are supportive and include transfusions, splenectomy, and chelation.

91 ry spleen) and laparoscopic in 2 (completion splenectomy, and cyst excision).

92 ncluding gastrojejunostomy, cholecystectomy, splenectomy, and distal pancreatectomy have been perform

93 nt correlation between methemoglobin levels, splenectomy, and factors that modify the degree of globi

94 rpura for more than 3 months, had a previous splenectomy, and had a platelet count less than 50 x 10(

95 use of rituximab, increased plasma exchange, splenectomy, and immunosuppressive options, including cy

96 cium, pre-transfusion hemoglobin, history of splenectomy, and liver iron concentration.

97 onor-specific antibody, absence of recipient splenectomy, and liver-inclusive graft type.

98 he increased thrombotic risk associated with splenectomy, and patients with hemoglobinopathies is a p

99 s, type of immunosuppression, recipient age, splenectomy, and treatment of rejection were significant

100 imus and sirolimus maintenance therapy, with splenectomy, anti-CD20 and daily alpha-Gal polymer.

101 rituximab leads to response rates similar to splenectomy ( approximately 70%), but rituximab-induced

102 Patients who undergo splenectomy are at greatly increased risk for overwhelmi

103 raft recipients, and particularly those with splenectomy are at high risk of developing GVHD after tr

104 We conclude that ITP patients post splenectomy are at increased risk for AbVTE, VTE, and se

105 Because patients who have undergone splenectomy are considered at increased risk of bacteria

106 , vincristine, or cyclosporine A; or salvage splenectomy are considered.

107 erm risks, the indications for and timing of splenectomy are debated in the medical community.

108 Advanced age and splenectomy are risk factors for PAH in this patient pop

109 Because subjects with autoimmunity had splenectomy at a significantly older age than participan

110 eroid-based immunosuppression protocol and a splenectomy at the time of rBEL implantation reduced the

111 l involving pretransplant plasmapheresis and splenectomy at the time of transplant (n=23).

112 eadmitted patients (4.5%) who did not have a splenectomy at their index hospitalization, leading to a

113 ft outcomes when compared most frequently to splenectomy-based protocols.

114 Moreover, splenectomy before RSD blocked monocyte trafficking to t

115 Splenectomy before subthreshold stress attenuated macrop

116 erm risk of sepsis in patients who underwent splenectomy before, during, and after implementation of

117 arious hematological disorders who underwent splenectomy between 1998 and 2009 were followed until de

118 uality Improvement Program data for elective splenectomy between January 1, 2005, and December 31, 20

119 a risk of splenic injury, which may require splenectomy, but predictors of such events remain uncert

120 spleens in oncologic patients who underwent splenectomy can be misinterpreted as a recurrence, espec

121 resent time, the use of immunotherapy before splenectomy can be recommended only in patients at high

122 Laparoscopic splenectomy can be safely performed during pregnancy.

123 n and antibody removal, without rituximab or splenectomy, can achieve long-term outcomes comparable t

124 Moreover, the hypothesis that incidental splenectomy carries a worse prognosis deserves attention

125 boembolic events, palpable splenomegaly, and splenectomy; chemotherapy exposure; leukemic transformat

126 The overall PR or CR to splenectomy combined with medical therapy was 84%.

127 he alloimmune response to the lymph nodes by splenectomy conferred the ability of B6.muMT(-/-) CD4 T

128 Splenectomy continues to provide the highest cure rate (

129 y), thymic irradiation (700 cGy), and native splenectomy (day 0), and received a 45-day course of int

130 Thirteen pigs underwent splenectomy (day 0); all received a blood transfusion.

131 th splenic injury, progression to incidental splenectomy decreased by 92% during the study period.

132 large datasets indicate contrasting rates of splenectomy depending on the expertise of the institutio

133 ing pneumococcal bacteremia after undergoing splenectomy despite having received numerous doses of PP

134 urrent guidelines recommend consideration of splenectomy, despite the known risks associated with sur

135 None of the patients with a history of splenectomy developed grade 3 or 4 hematotoxicity, and s

136 of Hbb-b2(Plt12/Plt12) mice was normal, and splenectomy did not correct the thrombocytopenia, sugges

137 hree patients required surgery: laparoscopic splenectomy due to infarct and abscess for 1 patient and

138 who were declared brain-dead or had emergent splenectomy due to trauma; control lungs (n = 20) were o

139 Splenectomy eliminated both the survival benefit of 6-hy

140 19% of whom underwent pre- or peritransplant splenectomy, experienced twice the adjusted risk of earl

141 nditioning regimen that included thymectomy, splenectomy, extracorporeal immunoadsorption of anti-alp

142 We studied 114 patients with ITP for whom splenectomy failed and who required additional therapy;

143 Median time to remission after splenectomy failure was 46 months (range, 1-437 months).

144 In regression analyses adjusting for age at splenectomy, follow-up time, sex, and calendar year of s

145 Male pigs underwent splenectomy followed by controlled hemorrhage until lact

146 Furthermore, splenectomy following RSD prevented the recurrence of an

147 help with patient selection before elective splenectomy for certain patients.

148 uraging evidence suggests that the effect of splenectomy for children is durable in the long term.

149 zed with rheumatoid vasculitis or to undergo splenectomy for Felty's syndrome, cervical spine fusion

150 nt the cases of three patients who underwent splenectomy for gastric carcinoid, gastric adenocarcinom

151 e pertaining to vascular complications after splenectomy for hematologic conditions and attempts to d

152 Elective splenectomy for hematologic conditions.

153 rdingly, the adverse effects and benefits of splenectomy for hematologic disorders and other conditio

154 ibed 15 or more consecutive patients who had splenectomy for ITP and that had data for 1 of these 3 o

155 Follow-up of patients who have undergone splenectomy for ITP reveals significant potential risks

156 We observed that splenectomy for ITP second-line treatment was more effec

157 Splenectomy for massive splenomegaly (>1500 g) provides

158 Splenectomy for massive splenomegaly can be performed sa

159 Splenectomy for massive splenomegaly was performed most

160 Current evidence supports alternatives to splenectomy for second-line management of patients with

161 utation in their granulocytes and undergoing splenectomy for therapeutical reasons.

162 onferred by C1 stimulation was eliminated by splenectomy, ganglionic-blocker administration or beta2-

163 oup for Nissen fundoplication, appendectomy, splenectomy, gastrostomy/jejunostomy, orchidopexy, and c

164 ary outcome-free survival rate was higher in splenectomy groups (84% for OS, 86% for LS) than Rituxim

165 lenectomized inpatients, patients undergoing splenectomy had a 5-fold higher rate of malaria presenta

166 Laparoscopic splenectomy has become the procedure of choice for most

167 Splenectomy has been a standard treatment for adult pati

168 efractory antibody-mediated rejection (AMR), splenectomy has been associated with surprisingly rapid

169 The role of splenectomy has been controversial in this patient popul

170 Age, splenectomy, hepatitis C, and smoking are significant un

171 A history of splenectomy, hepatitis C, smoking, or high white blood c

172 These beneficial effects of splenectomy hold true even for the most profoundly throm

173 Splenectomy, however, had no effect on monocyte accumula

174 ated with 2 or more therapy lines, including splenectomy, immunosuppressants, and rituximab.

175 h national inpatient register, who underwent splenectomy in 1970-2009.

176 spective cohort study of patients undergoing splenectomy in 2008 and 2009 using data from the America

177 1.9% (37.1% operable, 23.5% nonoperable) and splenectomy in 3.4% of patients (1.9% operable, 5.7% non

178 que group (0% vs. 10.5%; P=.03), requiring a splenectomy in 4 patients (4.7%).

179 ospitalization for rheumatoid vasculitis and splenectomy in Felty's syndrome decreased progressively

180 ospitalization for rheumatoid vasculitis and splenectomy in Felty's syndrome have decreased over the

181 The risk of hospitalization for splenectomy in Felty's syndrome was 71% lower in 1998-20

182 t malaria prophylaxis is warranted following splenectomy in malaria-endemic areas.

183 Splenectomy in mice with established HF reversed patholo

184 isks of malaria and other outcomes following splenectomy in patients attending a hospital in Papua, I

185 No study has directly compared rituximab to splenectomy in patients with chronic immune thrombocytop

186 was to compare the efficacy of Rituximab to splenectomy in persistent or chronic ITP patients.

187 y because of long-term immunosuppression and splenectomy in refractory cases.

188 usion and iron-chelation therapy, as well as splenectomy in specific cases.

189 strictly localized to spleen, she underwent splenectomy, in suspicion of lymphoma.

190 Indications for splenectomy included: thrombocytopenia refractory to (64

191 Incidental accidental splenectomy increased the overall risk of mortality (HR:

192 Splenectomy increases the risk of severe and fatal infec

193 nts, rituximab was found to be equivalent to splenectomy, indicating that this invasive surgical proc

194 time less than 60 min, absence of recipient splenectomy, interleukin-2 receptor antagonist induction

195 Splenectomy is a commonly performed operation; however,

196 Splenectomy is associated with a high risk of malaria, g

197 Splenectomy is considered acceptable for patients with r

198 Nonetheless, splenectomy is invasive, irreversible, associated with p

199 and persistent severe thrombocytopenia after splenectomy is minimal.

200 Splenectomy is not essential for successful ABO-incompat

201 s in only 4% of patients; therefore, routine splenectomy is not recommended.

202 The most widely recognized long-term risk of splenectomy is overwhelming bacterial infection.

203 sses diverse underlying conditions for which splenectomy is performed, diverse thrombotic complicatio

204 Splenectomy is usually proposed when a second-line thera

205 patible kidney transplantation have employed splenectomy, its utility is unproven.

206 se, lower incidence of treatment failure and splenectomy, less bleeding and fewer blood transfusions,

207 Splenectomy, loss of SIGN-R1(+) cells in the splenic mar

208 stinction between open (OS) and laparoscopic splenectomy (LS) was analyzed.

209 LDLT followed by thymoglobulin induction and splenectomy, maintenance with tacrolimus/cyclosporine (F

210 rs contributing to myelosuppression, whereas splenectomy may exert a protective effect.

211 al bacteremia in patients who have undergone splenectomy may indicate a genetically regulated failure

212 Splenectomy may play a role in the treatment of AMR refr

213 Splenectomy may reverse AMR by debulking PCs.

214 inage, and intra-abdominal bleeding (n = 3), splenectomy (n = 1), acute pancreatitis (n = 2), gastric

215 omib (n = 3), mycophenolate mofetil (n = 2), splenectomy (n = 2), and second HCT (n = 3).

216 ng iron-chelating treatment and a history of splenectomy need regular ophthalmic checkups because the

217 and hospital characteristics, the choice of splenectomy (odds ratio, 0.93; 95% CI, 0.66-1.31) vs ang

218 per 1-year increase; 95% CI, 1.06-1.15) and splenectomy (odds ratio, 9.31; 95% CI, 2.57-33.7).

219 ertook this study to determine the impact of splenectomy on transfusion requirements in patients with

220 Age (two studies) and splenectomy (one study) had the strongest association wi

221 on without long-term B-cell suppression from splenectomy or anti-CD20.

222 previously reported, 3 Gy of TBI with either splenectomy or CD154 blockade induced mixed chimerism an

223 Splenectomy or depletion of splenic macrophages by lipos

224 In peripheral blood from patients after splenectomy or in patients with sickle cell disease (SCD

225 plenomegaly and constitutional symptoms, and splenectomy or radiotherapy in selected patients.

226 Splenectomy or radiotherapy offers benefit, but careful

227 than OS, irrespective of the indication for splenectomy or the patient's clinical status.

228 ogy (OR 1.56, 95% CI 1.18-2.06), concomitant splenectomy (OR 1.99, 95% CI 1.25-3.17), and vascular re

229 ed the risk of splenic injury and incidental splenectomy (OR: 0.58; 95% CI: 0.41-0.80; and OR: 0.41;

230 he optimal timing for this therapy is before splenectomy, or after failure of splenectomy.

231 reference characteristics (no chemotherapy, splenectomy, or radiation therapy; male; attained age 28

232 ced- or conventional-intensity conditioning, splenectomy, or radiotherapy.

233 rates of in-hospital mortality, concomitant splenectomy, or total charges.

234 patients with TI and TM, age (P = 0.001) and splenectomy (P = 0.001) had the strongest association wi

235 ns of patients who received rituximab before splenectomy (P=0.0004).

236 Among them, four (27%) died following splenectomy performed for spontaneous spleen rupture, or

237 l antibody (Ab), four of whom also underwent splenectomy perioperatively.

238 omy alone (n=14), eculizumab alone (n=5), or splenectomy plus eculizumab (n=5), in addition to plasma

239 No patients treated with splenectomy plus eculizumab experienced graft loss.

240 t for patients manifesting early severe AMR, splenectomy plus eculizumab may provide an effective int

241 d eculizumab-alone groups at 1 year, whereas splenectomy plus eculizumab patients had almost no trans

242 In the hematologic malignancies, splenectomy produces a significant and longlasting resto

243 sk of surgery is an important consideration, splenectomy provides a high frequency of durable respons

244 usive trauma systems had significantly lower splenectomy rate (RR 0.79; 95% CI, 0.68-0.92) and lower

245 spitalization, leading to an overall delayed splenectomy rate of 1.2% (36 of 2967 patients).

246 m outcomes, such as readmissions and delayed splenectomy rate, are not well understood.

247 Secondary outcome was delayed splenectomy rate.

248 ivariate regression was performed to compare splenectomy rates, inpatient mortality, and costs betwee

249 Splenectomy reproduced antiinflammatory effects of enala

250 Splenectomy resulted in a dramatic enhancement of G-CSF-

251 Immunosuppression consisted of splenectomy, Rituximab (Anti-CD20), tacrolimus, sirolimu

252 ltirefractory ITP, defined as no response to splenectomy, rituximab, romiplostim, and eltrombopag.

253 e review 11 recipients, who underwent rescue splenectomy (RS) as a treatment of AMR within 3 months a

254 For persistence of symptoms after splenectomy, she underwent many instrumental examination

255 Splenectomy should be avoided.

256 Splenectomy should be considered safe and efficacious fo

257 ality and severe infections after incidental splenectomy should be kept in mind during surgery, and w

258 lihood of gastric variceal bleeding and that splenectomy should be performed to prevent hemorrhage.

259 In this study, we report that splenectomy significantly reduces systemic HMGB1 release

260 01, 25 consecutive adults with SLE underwent splenectomy specifically for thrombocytopenia.

261 platelet counts, concomitant ITP drugs, and splenectomy status) or by the number of previous ITP tre

262 re significant univariate risk factors, with splenectomy surfacing as the dominant risk factor over t

263 ression to assess the adjusted effect of the splenectomy technique on outcomes.

264 or those who received rituximab or underwent splenectomy, the overall graft survival was 94.5% (95% C

265 y, follow-up time, sex, and calendar year of splenectomy, there were no significant risk decreases af

266 options for symptomatic patients ranges from splenectomy to rituximab alone or combined with chemothe

267 The addition of splenectomy to this protocol only modestly added to the

268 mune thrombocytopenia, who had not undergone splenectomy, to receive the standard of care (77 patient

269 ty, rates of perioperative complications and splenectomy, total charges, and length of stay.

270 ared with 1% in patients who did not undergo splenectomy; venous thromboembolism (VTE) (deep venous t

271 ble living donor kidney transplantation with splenectomy versus a protocol involving intensive posttr

272 nous thrombosis and pulmonary embolus) after splenectomy was 4.3% compared with 1.7% in patients who

273 Early partial or complete response rate to splenectomy was 88%.

274 Splenectomy was associated with a higher adjusted risk o

275 nd 50% of children under the age of 6 years; splenectomy was associated with a significant improvemen

276 Splenectomy was associated with development of portal ve

277 Indication for splenectomy was hereditary spherocytosis (111), immune t

278 y developed grade 3 or 4 hematotoxicity, and splenectomy was inversely associated with the incidence

279 No splenectomy was needed.

280 After May 2003, splenectomy was not performed and a protocol that involv

281 protection was abolished in animals in which splenectomy was performed 7 days before VNS and IRI.

282 er an average of 11 days of ST, laparoscopic splenectomy was performed for rescue.

283 Splenectomy was performed in 1344 patients (78.4%) for b

284 antation, 88 patients received chemotherapy; splenectomy was performed in 24 patients.

285 Splenectomy was performed in 36 of 799 readmitted patien

286 nts, and conventional evisceration including splenectomy was performed in remaining six recipients.

287 D) 3, HLA-DSA remained negative but a rescue splenectomy was performed.

288 ressure monitoring and blood sampling, and a splenectomy was performed.

289 Response to splenectomy was rated as: complete (CR: platelets >/=150

290 The presence of recipient splenectomy was significantly associated with the incide

291 as hampered by ineffective chemotherapy, and splenectomy was the major therapeutic approach to improv

292 Splenectomy was then performed.

293 ic artery ligation, hemiportocaval shunt, or splenectomy) was performed at the discretion of the oper

294 Predictors of splenic injury and incidental splenectomy were analyzed using multivariable logistic r

295 ered activity, and the protective effects of splenectomy were of particular interest.

296 with hematologic malignancies who underwent splenectomy were reviewed.

297 5 x 10(9)/L, more previous therapies, and/or splenectomy were somewhat lower.

298 Avoiding splenectomy while controlling hypersplenism by using cor

299 cient evidence to support the replacement of splenectomy with rituximab as a second-line treatment of

300 owever, risks depended on the indication for splenectomy, with SIRs varying from 3.4 (95% CI, 3.0-3.8